Milana Zaurova1, Robert S Hoffman2,3, David Vlahov4, Alex F Manini5. 1. Emergency Medicine Residency, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, NYU School of Medicine, New York, NY, USA. 3. New York City Poison Control Center, New York City Department of Health and Mental Hygiene, New York, NY, USA. 4. School of Nursing, University of California, San Francisco, CA, USA. 5. Division of Medical Toxicology, the Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, One Gustave Levy Place, Box 1620, New York, NY, 10029, USA. alex.manini@mssm.edu.
Abstract
INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are heterogeneous compounds originally intended as probes of the endogenous cannabinoid system or as potential therapeutic agents. We assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdose patients. METHODS: This subgroup analysis of a large (n = 3739) drug overdose cohort study involved consecutive ED patients at two urban teaching hospitals collected between 2009 and 2013. Clinical characteristics of patients with the exposure to SCRAs (SRCA subgroup) were compared with those from patients who smoked traditional cannabinoids (marijuana subgroup). Data included demographics, exposure details, vital signs, mental status, and basic chemistries gathered as part of routine clinical care. Study outcomes included altered mental status and cardiotoxicity. RESULTS: Eighty-seven patients reported exposure to any cannabinoid, of whom 17 reported SCRAs (17 cases, 70 controls, mean age 38.9 years, 77 % males, 31 % Hispanic). There were no significant differences between SRCA and marijuana with respect to demographics (age, gender, and race/ethnicity), exposure history (suicidality, misuse, and intent), vital signs, or serum chemistries. Mental status varied between SRCA and marijuana, with agitation significantly more likely in SCRA subgroup (OR = 3.8, CI = 1.2-11.9). Cardiotoxicity was more pronounced in the SCRA subgroup with dysrhythmia significantly more likely (OR = 9.2, CI = 1.0-108). CONCLUSIONS: In the first clinical study comparing the adverse effects of SCRA overdose vs. marijuana controls in an ED population, we found that SCRA overdoses had significantly pronounced neurotoxicity and cardiotoxicity compared with marijuana.
INTRODUCTION: Synthetic cannabinoid receptor agonists (SCRAs) are heterogeneous compounds originally intended as probes of the endogenous cannabinoid system or as potential therapeutic agents. We assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdosepatients. METHODS: This subgroup analysis of a large (n = 3739) drug overdose cohort study involved consecutive ED patients at two urban teaching hospitals collected between 2009 and 2013. Clinical characteristics of patients with the exposure to SCRAs (SRCA subgroup) were compared with those from patients who smoked traditional cannabinoids (marijuana subgroup). Data included demographics, exposure details, vital signs, mental status, and basic chemistries gathered as part of routine clinical care. Study outcomes included altered mental status and cardiotoxicity. RESULTS: Eighty-seven patients reported exposure to any cannabinoid, of whom 17 reported SCRAs (17 cases, 70 controls, mean age 38.9 years, 77 % males, 31 % Hispanic). There were no significant differences between SRCA and marijuana with respect to demographics (age, gender, and race/ethnicity), exposure history (suicidality, misuse, and intent), vital signs, or serum chemistries. Mental status varied between SRCA and marijuana, with agitation significantly more likely in SCRA subgroup (OR = 3.8, CI = 1.2-11.9). Cardiotoxicity was more pronounced in the SCRA subgroup with dysrhythmia significantly more likely (OR = 9.2, CI = 1.0-108). CONCLUSIONS: In the first clinical study comparing the adverse effects of SCRA overdose vs. marijuana controls in an ED population, we found that SCRA overdoses had significantly pronounced neurotoxicity and cardiotoxicity compared with marijuana.
Authors: Lina T Al Kury; Oleg I Voitychuk; Keun-Hang Susan Yang; Faisal T Thayyullathil; Petro Doroshenko; Ali M Ramez; Yaroslav M Shuba; Sehamuddin Galadari; Frank Christopher Howarth; Murat Oz Journal: Br J Pharmacol Date: 2014-07 Impact factor: 8.739
Authors: Alison M Dines; David M Wood; Miguel Galicia; Christopher M Yates; Fridtjof Heyerdahl; Knut Erik Hovda; Isabelle Giraudon; Roumen Sedefov; Paul I Dargan Journal: J Med Toxicol Date: 2015-12
Authors: Robert J Tait; David Caldicott; David Mountain; Simon L Hill; Simon Lenton Journal: Clin Toxicol (Phila) Date: 2015-11-15 Impact factor: 4.467
Authors: Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis Journal: Drug Alcohol Depend Date: 2014-08-18 Impact factor: 4.492
Authors: Ulrich S Zimmermann; Patricia R Winkelmann; Max Pilhatsch; Josef A Nees; Rainer Spanagel; Katja Schulz Journal: Dtsch Arztebl Int Date: 2009-07-03 Impact factor: 5.594
Authors: Sarah Ann R Anderson; Anna M Oprescu; Diane Calello; Andrew Monte; Peter S Dayan; Yasmin L Hurd; Alex F Manini Journal: Pediatrics Date: 2019-07-08 Impact factor: 7.124
Authors: Liesl K Janssens; Simon Hudson; David M Wood; Caitlin Wolfe; Paul I Dargan; Christophe P Stove Journal: Arch Toxicol Date: 2022-08-12 Impact factor: 6.168
Authors: Melanie Bechard; Paula Cloutier; Isac Lima; Mina Salamatmanesh; Roger Zemek; Maala Bhatt; Sinthuja Suntharalingam; Paul Kurdyak; Melissa Baker; William Gardner Journal: CMAJ Open Date: 2022-02-08